Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Receivables (2016 - 2025)

Historic Receivables for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $3.7 million.

  • Utah Medical Products' Receivables rose 13.44% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 13.44%. This contributed to the annual value of $4.1 million for FY2024, which is 1737.39% up from last year.
  • Per Utah Medical Products' latest filing, its Receivables stood at $3.7 million for Q3 2025, which was up 13.44% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Receivables ranged from a high of $6.0 million in Q3 2022 and a low of $3.5 million during Q3 2023
  • For the 5-year period, Utah Medical Products' Receivables averaged around $4.3 million, with its median value being $3.9 million (2025).
  • As far as peak fluctuations go, Utah Medical Products' Receivables skyrocketed by 3759.92% in 2022, and later plummeted by 4221.08% in 2023.
  • Over the past 5 years, Utah Medical Products' Receivables (Quarter) stood at $5.3 million in 2021, then increased by 8.19% to $5.7 million in 2022, then tumbled by 39.02% to $3.5 million in 2023, then grew by 17.37% to $4.1 million in 2024, then dropped by 9.01% to $3.7 million in 2025.
  • Its Receivables was $3.7 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.9 million in Q1 2025.